Edwards Lifesciences Corp Stock Working Capital

EW Stock

USD 71.27 0.79 1.12%

Edwards Lifesciences Corp fundamentals help investors to digest information that contributes to Edwards Lifesciences' financial success or failures. It also enables traders to predict the movement of Edwards Stock. The fundamental analysis module provides a way to measure Edwards Lifesciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Edwards Lifesciences stock.

	Last Reported	Projected for Next Year
Net Working Capital	2.8 B	2.2 B
Change In Working Capital	-526.3 M	-500 M

Net Working Capital is likely to drop to about 2.2 B in 2024. Change In Working Capital is likely to climb to about (500 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Edwards Lifesciences Corp Company Working Capital Analysis

Edwards Lifesciences' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Edwards Lifesciences Working Capital

2.84 B

Most of Edwards Lifesciences' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Edwards Lifesciences Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Edwards Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Edwards Lifesciences is extremely important. It helps to project a fair market value of Edwards Stock properly, considering its historical fundamentals such as Working Capital. Since Edwards Lifesciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Edwards Lifesciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Edwards Lifesciences' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Retained Earnings	Net Receivables	Good Will	Total Liab	Total Current Assets	Net Debt	Accounts Payable	Long Term Debt	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Treasury Stock	Short Term Investments	Net Tangible Assets	Capital Surpluse	Long Term Investments	Long Term Debt Total	Short Long Term Debt	Cash And Equivalents	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.92	0.97	0.7	0.76	0.96	-0.68	0.73	0.4	-0.62	0.54	0.92	0.97	0.46	-0.68	0.28	0.97	0.88	0.75	0.6	0.27	0.05	0.86	0.89	0.83
Total Stockholder Equity	0.99		0.95	0.97	0.66	0.67	0.94	-0.68	0.75	0.34	-0.66	0.53	0.94	0.99	0.39	-0.69	0.24	0.99	0.85	0.73	0.53	0.27	0.05	0.91	0.92	0.87
Retained Earnings	0.92	0.95		0.93	0.45	0.53	0.91	-0.66	0.58	0.35	-0.51	0.37	0.91	0.95	0.41	-0.78	0.3	0.96	0.78	0.6	0.57	0.42	0.02	0.9	0.85	0.84
Net Receivables	0.97	0.97	0.93		0.61	0.68	0.95	-0.75	0.67	0.28	-0.62	0.47	0.89	0.97	0.52	-0.64	0.2	0.95	0.84	0.64	0.53	0.29	0.05	0.85	0.9	0.8
Good Will	0.7	0.66	0.45	0.61		0.81	0.56	-0.35	0.88	0.37	-0.74	0.76	0.59	0.64	0.15	-0.25	-0.07	0.61	0.79	0.68	0.34	-0.08	-0.05	0.58	0.69	0.58
Total Liab	0.76	0.67	0.53	0.68	0.81		0.74	-0.5	0.61	0.6	-0.37	0.39	0.63	0.64	0.59	-0.54	0.35	0.62	0.89	0.75	0.68	0.07	-0.05	0.54	0.62	0.55
Total Current Assets	0.96	0.94	0.91	0.95	0.56	0.74		-0.76	0.55	0.44	-0.47	0.39	0.85	0.92	0.59	-0.71	0.41	0.92	0.85	0.62	0.69	0.33	0.13	0.78	0.83	0.73
Net Debt	-0.68	-0.68	-0.66	-0.75	-0.35	-0.5	-0.76		-0.44	-0.26	0.42	-0.11	-0.63	-0.68	-0.61	0.6	-0.06	-0.68	-0.63	-0.36	-0.48	-0.26	-0.51	-0.55	-0.75	-0.54
Accounts Payable	0.73	0.75	0.58	0.67	0.88	0.61	0.55	-0.44		0.21	-0.85	0.7	0.73	0.75	0.02	-0.34	-0.19	0.74	0.72	0.71	0.2	0.0	0.11	0.76	0.83	0.77
Long Term Debt	0.4	0.34	0.35	0.28	0.37	0.6	0.44	-0.26	0.21		-0.08	0.11	0.3	0.29	0.28	-0.7	0.39	0.32	0.6	0.44	0.93	0.4	0.01	0.21	0.26	0.21
Short Term Debt	-0.62	-0.66	-0.51	-0.62	-0.74	-0.37	-0.47	0.42	-0.85	-0.08		-0.67	-0.6	-0.68	0.1	0.18	0.25	-0.66	-0.54	-0.49	-0.09	0.2	-0.09	-0.62	-0.75	-0.63
Intangible Assets	0.54	0.53	0.37	0.47	0.76	0.39	0.39	-0.11	0.7	0.11	-0.67		0.44	0.5	-0.26	0.02	-0.29	0.49	0.41	0.35	0.08	0.13	-0.01	0.41	0.49	0.39
Common Stock	0.92	0.94	0.91	0.89	0.59	0.63	0.85	-0.63	0.73	0.3	-0.6	0.44		0.95	0.35	-0.73	0.18	0.95	0.77	0.76	0.48	0.23	0.07	0.91	0.87	0.97
Property Plant Equipment	0.97	0.99	0.95	0.97	0.64	0.64	0.92	-0.68	0.75	0.29	-0.68	0.5	0.95		0.39	-0.67	0.19	0.99	0.83	0.7	0.49	0.25	0.06	0.92	0.93	0.9
Current Deferred Revenue	0.46	0.39	0.41	0.52	0.15	0.59	0.59	-0.61	0.02	0.28	0.1	-0.26	0.35	0.39		-0.48	0.53	0.37	0.56	0.32	0.53	0.14	-0.02	0.33	0.39	0.26
Treasury Stock	-0.68	-0.69	-0.78	-0.64	-0.25	-0.54	-0.71	0.6	-0.34	-0.7	0.18	0.02	-0.73	-0.67	-0.48		-0.43	-0.71	-0.69	-0.65	-0.82	-0.49	-0.07	-0.64	-0.58	-0.66
Short Term Investments	0.28	0.24	0.3	0.2	-0.07	0.35	0.41	-0.06	-0.19	0.39	0.25	-0.29	0.18	0.19	0.53	-0.43		0.26	0.34	0.32	0.5	-0.03	-0.21	0.24	0.09	0.15
Net Tangible Assets	0.97	0.99	0.96	0.95	0.61	0.62	0.92	-0.68	0.74	0.32	-0.66	0.49	0.95	0.99	0.37	-0.71	0.26		0.82	0.71	0.51	0.27	0.08	0.93	0.92	0.89
Capital Surpluse	0.88	0.85	0.78	0.84	0.79	0.89	0.85	-0.63	0.72	0.6	-0.54	0.41	0.77	0.83	0.56	-0.69	0.34	0.82		0.74	0.71	0.19	-0.07	0.78	0.83	0.71
Long Term Investments	0.75	0.73	0.6	0.64	0.68	0.75	0.62	-0.36	0.71	0.44	-0.49	0.35	0.76	0.7	0.32	-0.65	0.32	0.71	0.74		0.47	0.02	-0.13	0.69	0.61	0.73
Long Term Debt Total	0.6	0.53	0.57	0.53	0.34	0.68	0.69	-0.48	0.2	0.93	-0.09	0.08	0.48	0.49	0.53	-0.82	0.5	0.51	0.71	0.47		0.49	0.03	0.36	0.42	0.34
Short Long Term Debt	0.27	0.27	0.42	0.29	-0.08	0.07	0.33	-0.26	0.0	0.4	0.2	0.13	0.23	0.25	0.14	-0.49	-0.03	0.27	0.19	0.02	0.49		0.06	0.17	0.14	0.11
Cash And Equivalents	0.05	0.05	0.02	0.05	-0.05	-0.05	0.13	-0.51	0.11	0.01	-0.09	-0.01	0.07	0.06	-0.02	-0.07	-0.21	0.08	-0.07	-0.13	0.03	0.06		0.01	0.23	0.06
Net Invested Capital	0.86	0.91	0.9	0.85	0.58	0.54	0.78	-0.55	0.76	0.21	-0.62	0.41	0.91	0.92	0.33	-0.64	0.24	0.93	0.78	0.69	0.36	0.17	0.01		0.92	0.93
Net Working Capital	0.89	0.92	0.85	0.9	0.69	0.62	0.83	-0.75	0.83	0.26	-0.75	0.49	0.87	0.93	0.39	-0.58	0.09	0.92	0.83	0.61	0.42	0.14	0.23	0.92		0.87
Capital Stock	0.83	0.87	0.84	0.8	0.58	0.55	0.73	-0.54	0.77	0.21	-0.63	0.39	0.97	0.9	0.26	-0.66	0.15	0.89	0.71	0.73	0.34	0.11	0.06	0.93	0.87

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Edwards Lifesciences

Working Capital Over Time

Edwards Capital Surpluse

Capital Surpluse

1.18 Billion

At this time, Edwards Lifesciences' Capital Surpluse is fairly stable compared to the past year.

According to the company's disclosures, Edwards Lifesciences Corp has a Working Capital of 2.84 B. This is much higher than that of the Health Care Equipment & Supplies sector and 108.7% higher than that of the Health Care industry. The working capital for all United States stocks is 92.15% lower than that of the firm.

Edwards Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Edwards Lifesciences' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Edwards Lifesciences could also be used in its relative valuation, which is a method of valuing Edwards Lifesciences by comparing valuation metrics of similar companies.

Edwards Lifesciences is currently under evaluation in working capital category among its peers.

Edwards Lifesciences ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Edwards Lifesciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Edwards Lifesciences' managers, analysts, and investors.

Environmental

Governance

Social

Edwards Fundamentals

	Return On Equity	0.19
	Return On Asset	0.11
	Profit Margin	0.66 %
	Operating Margin	0.29 %
	Current Valuation	37.83 B
	Shares Outstanding	589.8 M
	Shares Owned By Insiders	0.91 %
	Shares Owned By Institutions	85.84 %
	Number Of Shares Shorted	7.7 M
	Price To Earning	32.77 X
	Price To Book	4.35 X
	Price To Sales	6.58 X
	Revenue	6 B
	Gross Profit	4.3 B
	EBITDA	1.53 B
	Net Income	1.4 B
	Cash And Equivalents	769 M
	Cash Per Share	2.81 X
	Total Debt	694.9 M
	Debt To Equity	0.11 %
	Current Ratio	3.83 X
	Book Value Per Share	16.18 X
	Cash Flow From Operations	895.8 M
	Short Ratio	1.31 X
	Earnings Per Share	2.59 X
	Price To Earnings To Growth	6.47 X
	Target Price	76.39
	Number Of Employees	19.8 K
	Beta	1.12
	Market Capitalization	41.57 B
	Total Asset	9.36 B
	Retained Earnings	8.99 B
	Working Capital	2.84 B
	Current Asset	2.05 B
	Current Liabilities	476.2 M
	Net Asset	9.36 B

About Edwards Lifesciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Edwards Lifesciences Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Edwards Lifesciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Edwards Lifesciences Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Edwards Stock Analysis

When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC